ID   MCF-7 RR2
AC   CVCL_IU97
SY   MCF-7_RR2
DR   cancercelllines; CVCL_IU97
DR   Cosmic; 2553505
DR   Wikidata; Q54904324
RX   PubMed=27279227;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:9168; Sirolimus (Rapamycin).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3942; MTOR; Simple; p.Phe2108Leu; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=27279227).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 13
//
RX   PubMed=27279227; DOI=10.1038/nature17963;
RA   Rodrik-Outmezguine V.S., Okaniwa M., Yao Z., Novotny C.J.,
RA   McWhirter C., Banaji A., Won H., Wong W., Berger M., de Stanchina E.,
RA   Barratt D.G., Cosulich S., Klinowska T., Rosen N., Shokat K.M.;
RT   "Overcoming mTOR resistance mutations with a new-generation mTOR
RT   inhibitor.";
RL   Nature 534:272-276(2016).
//